Medicare forced to pay for unproven devices for four years straight
S. 1717 — Ensuring Patient Access to Critical Breakthrough Products Act of 2025 · Filed by Todd Young (R-IN) · 5 cosponsors · Introduced May 12, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill creates a fast-track Medicare coverage pathway for medical devices that the FDA has designated as 'breakthrough' innovations. Manufacturers can apply for a 4-year 'transitional coverage period' during which Medicare must cover their device, and the government must issue a final coverage decision before that period ends. The bill appropriates $10 million annually through 2031 to administer the program.
Why we flagged it
The bill's core function is to guarantee Medicare payment for FDA-designated breakthrough devices during a 4-year window with minimal clinical-evidence thresholds, effectively subsidizing device manufacturers' market entry at public expense. While framed as 'patient access,' the mechanism prioritizes manufacturer certainty over evidence-based coverage.
What the text implies
- The bill requires Medicare coverage based solely on FDA priority-review designation, not on clinical proof of superiority or cost-effectiveness—a lower evidentiary bar than standard Medicare coverage policy, potentially locking in payment for devices that may not outperform existing alternatives.
- The 4-year transitional period creates a guaranteed revenue stream for device manufacturers regardless of real-world clinical outcomes, shifting financial risk from industry to Medicare and taxpayers.
The full analysis lists 4 implications of this text.
Who stands to gain
medical device manufacturers (especially those with FDA priority-review designations); biotech and medtech companies with breakthrough-device pipelines